KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Assets (2018 - 2026)

Twist Bioscience has reported Assets over the past 9 years, most recently at $676.2 million for Q1 2026.

  • Quarterly Assets rose 13.53% to $676.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $676.2 million through Mar 2026, up 13.53% year-over-year, with the annual reading at $641.9 million for FY2025, 4.48% up from the prior year.
  • Assets was $676.2 million for Q1 2026 at Twist Bioscience, up from $638.1 million in the prior quarter.
  • Over five years, Assets peaked at $1.0 billion in Q1 2022 and troughed at $595.6 million in Q1 2025.
  • The 5-year median for Assets is $702.8 million (2024), against an average of $753.3 million.
  • Year-over-year, Assets surged 50.84% in 2022 and then dropped 21.25% in 2024.
  • A 5-year view of Assets shows it stood at $910.0 million in 2022, then fell by 19.47% to $732.8 million in 2023, then fell by 16.95% to $608.6 million in 2024, then rose by 4.85% to $638.1 million in 2025, then grew by 5.98% to $676.2 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Assets are $676.2 million (Q1 2026), $638.1 million (Q4 2025), and $641.9 million (Q3 2025).